Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06812325 · ClinicalTrials.gov registry record · Phase 3
A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
A Phase 3 study of Thyroid Eye Disease (TED), sponsored by Viridian Therapeutics.
- Active
- Registry status
- Phase 3
- Development phase
- 321
- Enrollment target
- 20
- Study locations
NCT06812325 is a Phase 3 study of Thyroid Eye Disease (TED) that is active but no longer recruiting, run by Viridian Therapeutics. The registered enrollment target is 321 participants. The trial reports 20 study locations across 4 states.
The verdict
NCT06812325, a Phase 3 study of Thyroid Eye Disease (TED), is active but no longer recruiting, sponsored by Viridian Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 321 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a clinical trial assessing the safety and tolerability of an investigational drug, VRDN-003, in participants with Thyroid Eye Disease (TED).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG VRDN-003
Study Locations (20)
Florida
- C A Clinical Trial Corp. - Cape Coral
- Herco Medical and Research Center - Coral Gables
- Alfa Medical Research - Davie
- D H Doral Research Center - Doral
- Eye Centers of Florida - Fort Myers
- Sina Medical Center - Homestead
- East Coast Institute for Research, LLC - Jacksonville
- Southern Clinical Research LLC - Miami
- Retreat Medical Research - Miami
- Continental Clinical Research - Miami
- Edward Jenner Research Group LLC - Plantation
- Sarasota Retina Institute - Sarasota
California
- United Medical Research Institute - Inglewood
- Orbital Plastics - Newport Beach
- California Eye Specialists Medical Group INC - Pasadena
- FOMAT Medical Research - Pismo Beach
- Pacific Neuroscience Institute - Santa Monica
- Pacific Neuroscience Institute at Saint John's Physician Partners - Torrance
Arizona
- Catalina Eye Care - Tuscon
Illinois
- Advanced Quality Medical Research - Orland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 321 participants |
| Start Date | 2025-02-03 |
| Est. Completion | 2026-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06812325
The ClinicalTrials.gov registry entry for NCT06812325 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 321 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Viridian Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Thyroid Eye Disease (TED) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06812325 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT06812325 about?
NCT06812325 is a clinical study titled "A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)". This is a clinical trial assessing the safety and tolerability of an investigational drug, VRDN-003, in participants with Thyroid Eye Disease (TED).
What is the current status of trial NCT06812325?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 321 participants. The study started on 2025-02-03. Estimated completion is 2026-10.
What conditions does trial NCT06812325 study?
This clinical trial studies the following conditions: Thyroid Eye Disease (TED).
What interventions are being tested in trial NCT06812325?
The interventions under investigation include: Placebo (DRUG), VRDN-003 (DRUG).
Who is sponsoring clinical trial NCT06812325?
This trial is sponsored by Viridian Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06812325 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.